Clinical Scorecard: Effectiveness of COVID-19 Vaccination in Individuals with Hematologic Cancers: Findings from a Nationwide Cohort Analysis
At a Glance
Category
Detail
Condition
Hematologic malignancies and COVID-19
Key Mechanisms
Immunocompromised state due to malignancy and oncolytic therapy increases risk of severe COVID-19; vaccine effectiveness varies by malignancy type, treatment, and time since vaccination
Target Population
Adults with a history of hematologic malignancies infected with SARS-CoV-2
Care Setting
Population-based, nationwide healthcare setting including hospital and outpatient care
Key Highlights
Patients with hematologic malignancies have the highest risk of severe COVID-19 compared to those with solid malignancies or no malignancies.
COVID-19 vaccine effectiveness against severe disease in hematologic malignancy patients reached up to 74%, influenced by variant period, vaccination number, and timing.
Risk of severe COVID-19 is elevated in patients recently diagnosed or receiving tumor-specific treatments such as CD38/CD20 antibodies, proteasome inhibitors, and protein kinase inhibitors.
Guideline-Based Recommendations
Diagnosis
Identify patients with hematologic malignancies who test positive for SARS-CoV-2 for risk stratification.
Consider timing since malignancy diagnosis and current treatment regimens when assessing COVID-19 risk.
Management
Prioritize COVID-19 vaccination including extended dosing schedules (e.g., third dose) for patients with hematologic malignancies.
Implement additional prevention and therapeutic strategies tailored to high-risk patients with hematologic malignancies.
Monitoring & Follow-up
Monitor for severe COVID-19 outcomes including hospitalization and death within 28 days post SARS-CoV-2 infection.
Track vaccination status and time intervals since last vaccination to evaluate ongoing protection.
Risks
Recognize elevated risk of severe COVID-19 in patients on tumor-specific therapies such as CD38/CD20 antibodies, proteasome inhibitors, and protein kinase inhibitors.
Acknowledge persistent elevated risk despite vaccination compared to non-malignant populations.
Patient & Prescribing Data
Adults with hematologic malignancies infected with SARS-CoV-2
Vaccine effectiveness varies by malignancy type, treatment, and time since vaccination; extended vaccination schedules improve protection; tumor-specific therapies may increase risk of severe COVID-19.
Clinical Best Practices
Prioritize COVID-19 vaccination with additional doses for patients with hematologic malignancies.
Assess individual risk based on malignancy type, treatment regimen, and time since diagnosis.
Use nationwide registry data to inform personalized prevention and treatment strategies.
Maintain vigilance for severe COVID-19 outcomes even in vaccinated patients with hematologic malignancies.
by Quincy Hofsink, Birgit I Lissenberg-Witte, Sabine Haggenburg, Abraham Goorhuis, Mette D Hazenberg, Caroline E Rutten, Paul den Tex, Elisabeth G E de Vries, Astrid A M van der Veldt, Jeanet M Kemmeren, Nicolette F de Keizer, Peter C Huijgens, Avinash G Dinmohamed, Annika van Roon, Joyce Pijpers, Caren van Roekel, Susan van den Hof, Susan J M Hahné, Brechje de Gier, Jarom Heijmans, Inger S Nijhof
